The single use of this product is slightly better than atenolol or hydrochlorothiazide in the treatment of mild and moderate hypertension. In the treatment of severe hypertension, the effect is the same as metoprolol or nifedipine. The treatment of congestive heart failure is superior to captopril, and can increase the left ventricular ejection fraction, improve the patient's mobility and improve the quality of life. Currently, this product is a second-line medicine for the treatment of hypertension and congestive heart failure.

This product is a lysine derivative of enalapril and has a potent angiotensin-converting enzyme inhibitory effect. Its characteristic is that it can produce pharmacological effect in vivo without liver transformation, and the effect appears late, but the effect is maintained for a long and stable time.